Page 3 - Generation Bio News Today

Generation Bio Co. (NASDAQ:GBIO – Get Free Report) Director Dannielle Appelhans purchased 12,000 shares of the firm’s stock in a transaction dated Monday, December 4th. The stock was bought at an average cost of $1.50 per share, for a total transaction of $18,000.00. Following the acquisition, the director now directly owns 12,000 shares in the […]

In a notable insider transaction, Rowland Charles A Jr, a director at Generation Bio Co, has significantly increased his stake in the company.

Check out this week’s medical marketing news, people on the move and industry chatter.

The Cambridge biotech startup is seeking to extend its cash into 2027.

Generation Bio Co. (NASDAQ:GBIO – Get Free Report) has been given an average rating of “Hold” by the six analysts that are covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12-month price target among analysts […]

-  Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics -  Proprietary cell-targeted LNP delivery system...

70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells Stealth...

70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells Stealth properties of cell-targeted lipid nanoparticle ...

TODAY’S GAME PLAN: from the trading desk, this is not research DATA/HEADLINES 8:30ET Chicago Fed Nat Activity Index TODAY’S HIGHLIGHTS: California Governor Gavin Newsom is in China for weeklong trip Nine Republicans are running for House speaker 3 Chinese firms used parts of leopards and pangolins as ingredients in medicine products Global stocks

TD Cowen lowered shares of Generation Bio (NASDAQ:GBIO – Free Report) from an outperform rating to a market perform rating in a research report sent to investors on Thursday, Marketbeat.com reports. A number of other analysts have also recently commented on GBIO. Needham & Company LLC reaffirmed a buy rating and set a $14.00 price […]